We pride ourselves on our deep domain knowledge in healthcare, and subsector specialization across biopharma, medical technology, life sciences and healthcare services.
Our senior investment team has on average 20+ years of experience investing in the healthcare sector, and has fostered a valuable relationship network across the public and private corporate universe, KOLs, doctors, regulatory and legal experts, venture capital, industry specialists, consultants, sell-side research and investment banking.
Our culture is rooted in creativity, collaboration and an entrepreneurial spirit.
At PFM Health Sciences, we pride ourselves on fostering a meritocratic culture based on collaboration, transparency and integrity. Our team is a diverse group of individuals with decades of investment and industry experience who are tied together by intellectual curiosity, a willingness to adapt and a drive to succeed.
Our aim is to provide our team with a dynamic and entrepreneurial platform for growth.
Senior Investment Team
Brian is the firm’s Founder, Managing Partner, CIO and Portfolio Manager. He focuses on investing across the Healthcare sector and has been covering Healthcare since 1998. Brian started his career in 1996 at J.P. Morgan Asset Management (JPMAM). His initial role at JPMAM was as a convertible bond analyst before he was selected to become an equities analyst covering the Medtech and Healthcare Services subsectors. By the time Brian left JPMAM to join Pequot Capital Management (Pequot) in 2001, he had taken over coverage for the Biotech subsector. At the time of his hire, Pequot was in the process of separating into two firms and Brian joined the leaving team that would launch Andor Capital Management (Andor) and Brian was the Senior Biotechnology Analyst at Andor (2001-2004). At the inception of PFM Health Sciences (FKA Partner Fund Management) in 2004, the intention was to launch and establish a diversified strategy (inception November 2004) before launching a dedicated Healthcare strategy (PFM Healthcare Fund, L.P. inception December 2005). Since the outset of the firm, Brian has been responsible for all Healthcare-related investment activities. Brian is a graduate of The University of Pennsylvania with a B.S. in Economics and is a CFA® charterholder.
Prior to joining PFM Health Sciences in 2014, Anant was an Analyst for the Global Equities Fund at Omers Capital Markets (2011-2014). Before Omers, he was a Consulting Healthcare Analyst at Spencer Capital Management (2010-2011). Prior to Spencer Capital, Anant was an Analyst with Opus Point Partners (2008-2009) and a Resident Physician at Albert Einstein College of Medicine (2005-2008). Anant graduated from North Carolina State University with a B.S. in Zoology, received his M.D. from New York Medical College and received his MBA from Columbia Business School.
Prior to rejoining PFM, David was a Portfolio Manager at Balyasny Asset Management where he focused on Biopharma (2016-2021). From 2014-2016 he was a Seed and Early-Stage Investor at SummitVision Capital. Prior to this, he was a Senior Investment Analyst at Citadel (2011-2013). From 2009-2011, David was an Analyst covering Biopharma for PFM. Prior to PFM, he was an Analyst at J. Goldman & Co. (2006-2008), JPMorgan Chase & Co. (2004-2006), First Albany Capital (2003-2004), Wachovia Securities (2002-2003) and Robertson Stephens (2000-2002). David graduated from Colgate University with a B.A. in Molecular Biology and is a CFA® Charterholder.
Prior to rejoining PFM Health Sciences in 2019, Mark was an Analyst at Citadel and focused on Biotech/Pharma. From 2015-2017 he focused on Biotech/Pharma for PFM Health Sciences. From 2013-2015 Mark was a Senior Analyst in Therapeutics at Cresheim Capital. Before Cresheim Capital, he spent 6 years at SAC Capital, where he was a Portfolio Manager covering European Healthcare with SAC Global Investors, LLP, a Research Trader with SAC Capital Advisors, L.P. and a Senior Analyst in the Sigma Capital division (2006-2012). Prior to SAC Capital, he was a sell-side Equity Analyst with Piper Jaffray (2004-2006) and Prudential Securities (2001-2004). Mark began his career as a Research Coordinator in the PM&R department at Harvard Medical School (1999-2001) and earned both his M.A. and his B.A. in Neuroscience and Behavior from Wesleyan University.
Prior to joining PFM Health Sciences in 2020, Santhosh was a Principal at New Enterprise Associates (NEA) where he invested in early stage private companies in the Biopharma sector and served on the boards of companies in the cell therapy, targeted oncology, radiopharmaceuticals and gene editing fields. From 2016-2018 Santhosh was a Vice President at Cowen and Company in Equity Research, where he covered SMID Cap Biotech stocks across numerous therapeutic areas. He previously served as an Associate Director in Oncology Clinical Development at Pfizer (2013-2016) and as a Scientist in Oncology Preclinical Development at Takeda Pharmaceuticals (2012-2013). Santhosh graduated with a B.S. and M.S. in Chemical Engineering from the University of Madras and Texas A&M University, respectively. Santhosh earned his PhD in Bioengineering from the University of Pennsylvania and completed his postdoctoral work in Biochemistry and Molecular Biophysics at Columbia University. Santhosh is a CFA® Charterholder.
Prior to joining PFM Health Sciences in 2012, Vivek was an Analyst at Catapult Partners/Millennium LLP (2011-2012). Before Millennium, he was an Analyst/Sector Head at Argus/Sivik Healthcare (2002-2011). Prior to Sivik Healthcare, Vivek was an Executive Director of Equity Research with UBS Investment Bank (1999-2002), Vice President of Equity Research with Smith Barney (1993-1996) and an Analyst at Blue Cross Blue Shield of National Capital Area (1991-1993). Vivek is a graduate of Delhi University with a B.A. in Economics and received his MBA from the College of William and Mary.
Prior to joining PFM Health Sciences in 2007, Chris was a Principal and Portfolio Manager/Trader focusing on credit trading strategies with Barclays Global Investors (2003-2007). Before BGI, he was an Associate Vice President at Standish Mellon Asset Management (2001-2003). Chris graduated from Bentley College with a B.S. in Economics-Finance and is a CFA® charterholder.
Chief Compliance Officer
Chief Compliance Officer
Prior to joining PFM Health Sciences in 2011, Darin was the Chief Compliance Officer for Citadel’s asset management business and a Director and an Assistant General Counsel at Citadel LLC (2005-2011). Before Citadel, Darin was the Vice President of Legal and Compliance at Lehman Brothers Inc. (2004-2005) where he served as a member of Lehman’s Control Room. Prior to this role, he was a Corporate and Securities Associate with Thompson & Knight LLP (2001-2003). Darin graduated with a Bachelor of Business Administration and Masters in Professional Accounting from the McCombs School of Business at the University of Texas, and received his JD from the University of Texas School of Law. Darin is admitted to the State Bar of Texas and is Registered In-House Counsel in California.
Prior to joining PFM Health Sciences in 2007, Graham was a Managing Director in U.S. Equity Sales at Merrill Lynch (1997-2007). Before business school, he was a Private Wealth Advisor with Merrill Lynch (1992-1995). Graham is a graduate of the University of New Mexico with a degree in Marketing/Business Administration and received his MBA from UCLA’s Anderson School of Management.
Prior to joining PFM Health Sciences in 2007, Yuan was an Audit Senior Manager in the Asset Management Group at Ernst & Young LLP, New York (2006-2007). Prior to Ernst & Young LLP, she was the Controller and Chief Compliance Officer at Triatto Capital Management, LP (2004-2006). Before Triatto, Yuan was an Audit Manager in Asset Management Group at Ernst & Young, LLP, San Francisco (2000-2004). Before that, she worked at Publisher Group Incorporated as Lead Financial Accountant (1997-2000). Yuan is a graduate of the University of California Berkeley with a B.A. in Economics. She is also a California Certified Public Accountant.